

REMARKS

Applicant would like to thank Examiner Haq for discussing the present case with Applicants on September 8, 2011. Applicants discussed with Examiner Haq the best means to ensure acknowledgement of the continuing data and priority chain for the present application. Upon review of the file Applicants noticed that the filing receipt does not include the complete continuing data for the present application. Support for amendment and correction of the continuing data can be found in the Oath and Declaration and the Transmittal, which were both submitted with the filing of the present application on June 2, 2000.

Please issue a corrected filing receipt listing the "Continuing Data as Claimed by Applicant" as follows:

--This Application is a Divisional of United States Appln. 09/072,278 filed May 4, 1998 which is a Continuation of United States Appln. 08/532,837 filed October 5, 1995, which is a 371 Filing of PCT/EP94/01006 filed March 30, 1994, which claims priority of UK Application 94307491.2 filed April 8, 1993.--

A copy of the filing receipt with the correction noted is enclosed as well as a new Application Data Sheet.

Applicants believe that no fees are due with this filing. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936

/Christine McCormack/

Date: September 9, 2011

Christine McCormack
Attorney for Applicant
Reg. No. 61,331
(617) 871-8486